What are the recommended sliding-scale insulin dosing guidelines for adult patients, including dose adjustments based on glucose levels, body weight, renal function, and criteria for switching to a basal-bolus regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Sliding Scale Insulin Guidelines

Sliding scale insulin (SSI) alone is strongly discouraged for hospitalized adults with diabetes and should be replaced with basal-bolus or basal-plus regimens, except in limited circumstances of mild stress hyperglycemia in patients without diabetes. 1, 2

When SSI Should NOT Be Used

  • Never use SSI alone in patients with type 1 diabetes – these patients require basal insulin at all times, even when NPO, to prevent diabetic ketoacidosis 1, 2
  • Avoid SSI alone in patients with type 2 diabetes – randomized trials consistently show inferior glycemic control and higher rates of complications (wound infections, pneumonia, bacteremia, renal/respiratory failure) compared to basal-bolus regimens 2
  • Prolonged use of correction insulin without basal insulin is strongly discouraged in the inpatient setting for patients with established diabetes 1

Limited Acceptable Use of SSI

SSI alone may be appropriate only in these specific scenarios:

  • Patients without diabetes with mild stress hyperglycemia 2
  • Patients with type 2 diabetes with good metabolic control on oral agents at home who have mild hyperglycemia 2
  • Admission blood glucose <180 mg/dL – retrospective data shows 83-86% of patients with admission glucose <180 mg/dL achieve target control with SSI alone, versus only 18% with admission glucose ≥250 mg/dL 3

Critical caveat: Even in these limited scenarios, add basal insulin if glucose levels cannot be maintained below 180 mg/dL (10.0 mmol/L) 2

Recommended Alternative: Basal-Bolus Regimen

Initial Dosing for Insulin-Naive or Low-Dose Patients

  • Total daily dose: 0.3-0.5 units/kg body weight 2
  • Split 50/50: Half as basal insulin (once or twice daily), half as rapid-acting prandial insulin (divided before three meals) 2
  • Add correction doses of rapid-acting insulin on top of scheduled doses 2

Dose Adjustments for High-Risk Populations

Lower doses are mandatory for patients at increased hypoglycemia risk 2:

  • Age >65 years: Use lower end of dosing range
  • Renal insufficiency: Reduce doses; evidence supports lower insulin requirements with renal impairment 1, 2
  • Poor oral intake: Reduce doses to prevent hypoglycemia

Dose Adjustments for Patients on Home Insulin

  • If already on ≥0.6 units/kg/day at home: Reduce total daily dose by 20% during hospitalization to prevent hypoglycemia from reduced oral intake 2

Alternative: Basal-Plus Regimen (Safer Option)

For patients with mild hyperglycemia (glucose <200 mg/dL), decreased oral intake, or undergoing surgery, consider basal-plus instead of full basal-bolus 2:

  • Basal insulin: 0.1-0.25 units/kg/day as a single dose 2
  • Plus correction doses of rapid-acting insulin before meals or every 6 hours if NPO 2
  • Lower hypoglycemia risk compared to full basal-bolus (4-6 times lower risk than basal-bolus) 2

Critical Safety Considerations

Hypoglycemia Risk

  • Basal-bolus carries 4-6 times higher hypoglycemia risk than SSI (blood glucose ≤70 mg/dL: RR 5.75; ≤60 mg/dL: RR 4.21) 2
  • However, SSI results in significantly worse glycemic control with mean glucose 14.8 mg/dL higher than basal-bolus 4
  • Implement hypoglycemia protocols: Any glucose <70 mg/dL requires immediate treatment and review of insulin regimen 1

When to Transition from SSI to Scheduled Insulin

Transition immediately if:

  • Patient cannot maintain glucose <180 mg/dL on SSI alone 2
  • Patient has established diabetes (type 1 or type 2) 1, 2
  • Admission glucose ≥180 mg/dL 3

Insulin Types to Avoid

  • Premixed insulin (70/30): Associated with unacceptably high hypoglycemia rates; not recommended in hospital 2

Clinical Outcomes

The evidence clearly favors scheduled insulin over SSI 2:

  • Basal-bolus reduces composite complications (infections, organ failure)
  • Better glycemic control (mean glucose 14.8 mg/dL lower)
  • Despite higher hypoglycemia risk with basal-bolus, severe hypoglycemia remains rare in controlled settings (2.4% vs 0% with SSI) 4

The key clinical decision: Accept slightly higher hypoglycemia risk with basal-bolus to achieve better glycemic control and reduce complications, or use the safer basal-plus approach for mild hyperglycemia and high-risk patients 2.

References

2
Guideline

management of diabetes and hyperglycaemia in the hospital.

The Lancet Diabetes and Endocrinology, 2021

Related Questions

What insulin sliding‑scale protocol should be used for a hospitalized 70‑kg adult with normal renal function and type 2 diabetes or stress‑related hyperglycemia, including rapid‑acting insulin dosing based on glucose ranges, monitoring frequency, and dose adjustments?
How should I manage an adult patient whose blood glucose is 150–350 mg/dL despite using only a sliding‑scale insulin regimen?
In a 70‑year‑old female nursing home resident with finger‑stick blood glucose ranging from 70 to 500 mg/dL who is currently on a sliding‑scale regimen of insulin glargine (Lantus) 12 units when glucose >200 mg/dL and insulin lispro (Humalog) 6 units twice daily when glucose >200 mg/dL, what is the recommended treatment approach?
What high‑dose sliding‑scale insulin regimen (units per glucose range) should be used for a hospitalized type 2 diabetic patient who is nothing by mouth (NPO) and has no severe renal or hepatic failure?
What are the indications for continuous glucose monitoring (CGM) in patients with diabetes?
Should a 78-year-old woman who discontinued hormone replacement therapy 9 years ago restart systemic HRT, and what are the associated risks and non‑hormonal alternatives?
When can a patient with a tibial plateau fracture begin range-of-motion physical therapy?
What are the recommended pediatric dosing guidelines for niacin (nicotinic acid or nicotinamide) in infants, children, and adolescents?
What are the indications, dosing regimen, contraindications, and monitoring recommendations for losartan use in adult patients with hypertension, diabetic nephropathy, or heart failure with reduced ejection fraction?
How should an adult with a positive JAK2 V617F mutation be evaluated and managed?
In a patient with CT abdomen showing left renal hydronephrosis and hydroureter due to a tiny left distal ureteral stone (≈1.2–2 mm) with perinephric stranding and an elevated white blood cell count, what is the differential diagnosis and recommended treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.